RE: Webinar21 Jan 2022 14:37
Agree and thanks for heads up re Edison.
Here's a snippit :
Close to commercialisation
As of January 2022, Clarava and Tuteva have completed testing requirements in clinical validation trials, with results expected to be published in Q122. In preparation for commercialisation, Verici Dx gained a Clinical Laboratory Improvement Amendments certificate of registration in July 2021 to allow its state-of-the-art test labs in Tennessee to start operations if clinical validation results allow commercialisation. In January 2022, Verici Dx also obtained a Current Procedural Terminology code, a key component for US reimbursement, for Clarava and Tuteva. The last reported cash position (December 2021) was $10.3m and management expects to begin generating revenue in 2022, both of which should support further development of the Verici Dx platform.
GL.